{"product_id":"nxerapharma-business-model-canvas","title":"Nxera Pharma Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNxera Pharma Business Model Canvas: Downloadable Strategic Blueprint for Investors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Nxera Pharma's business model — a concise, actionable Business Model Canvas that maps value propositions, customer segments, partnerships, and revenue levers; perfect for investors, consultants, and founders seeking a ready-to-use, downloadable template to benchmark, plan, and scale with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Pharmaceutical Strategic Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNxera partners with AbbVie, Pfizer, and Eli Lilly on GPCR-targeted programs, sharing development costs and accessing late-stage clinical teams and commercial channels; these alliances covered ~45% of 2024 R\u0026amp;D spend and reduced Nxera’s binary phase III financing need by an estimated $120M. By end-2025 the collaborations remain core to platform validation and give global market reach across 60+ countries for the lead programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institution Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNxera Pharma partners with top universities and research centers to lead in structural biology and pharmacology, yielding 12 joint publications and 8 co‑discovered targets since 2022 that feed the StaR technology platform.\u003c\/p\u003e\n\u003cp\u003eThese collaborations accelerated early‑stage discovery, cutting target validation time by ~30% and contributing to a 2025 R\u0026amp;D pipeline valuation of $220M in immunology and related complex therapeutic areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Research and Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNxera relies on a network of high-quality CROs and CMOs to handle clinical trial execution and specialized manufacturing, enabling simultaneous advancement of multiple Phase 1\/2 programs; industry benchmarks show outsourcing cuts capex by ~60% and shortens time-to-clinic by ~30% (2024 BIO report). This model keeps Nxera lean, focusing internal R\u0026amp;D on discovery while partners scale ops to support projected 4–6 IND-enabling campaigns through 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJoint Venture and Regional Commercial Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNxera forms joint ventures and appoints regional commercial partners in Japan and the Asia-Pacific to handle local regulatory approval, market access, and distribution, targeting faster launch timelines and share-based revenue upside.\u003c\/p\u003e\n\u003cp\u003eIn 2025, Asia-Pacific accounted for ~32% of global pharma sales (~$460B) so local partners help Nxera access fragmented payers and achieve reimbursement within 12–24 months post-approval.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLeverages local regulatory teams\u003c\/li\u003e\n\u003cli\u003eRevenue-share or milestone deals\u003c\/li\u003e\n\u003cli\u003eTargets Japan first for higher ASPs\u003c\/li\u003e\n\u003cli\u003eReduces upfront capex and logistics risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial and Institutional Investors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStrategic ties with healthcare-focused VCs and institutional investors supply capital for Nxera’s long-term R\u0026amp;D and add strategic guidance plus industry connections to de-risk clinical programs.\u003c\/p\u003e\n\u003cp\u003eWith clinical-stage burn rates often $5–15M\/month, maintaining these relationships is essential; recent biotech IPOs in 2024 averaged $120M in proceeds, showing the scale partners can mobilize.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCapital for multi-year R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eStrategic guidance and board access\u003c\/li\u003e\n\u003cli\u003eIndustry partnerships and M\u0026amp;A channels\u003c\/li\u003e\n\u003cli\u003eMatches typical $5–15M\/month burn\u003c\/li\u003e\n\u003cli\u003eAccess to average $120M IPO pools (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNxera partners cut validation 30%, fund 45% R\u0026amp;D — $220M 2025 pipeline, −$120M phase‑III\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNxera’s strategic partners (AbbVie, Pfizer, Eli Lilly), universities, CROs\/CMOs, APAC commercial JVs, and healthcare VCs provided 45% of 2024 R\u0026amp;D funding, cut validation time ~30%, and underpin a 2025 pipeline value of $220M while reducing phase‑III financing need by ~$120M.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBig Pharma\u003c\/td\u003e\n\u003ctd\u003eCo‑dev\/commercial\u003c\/td\u003e\n\u003ctd\u003e45% R\u0026amp;D; −$120M phase‑III need\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademia\u003c\/td\u003e\n\u003ctd\u003eDiscovery\u003c\/td\u003e\n\u003ctd\u003e12 pubs; 8 targets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO\/CMO\u003c\/td\u003e\n\u003ctd\u003eTrials\/mfg\u003c\/td\u003e\n\u003ctd\u003e−60% capex; −30% TTC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPAC JVs\u003c\/td\u003e\n\u003ctd\u003eLocal launch\u003c\/td\u003e\n\u003ctd\u003e32% market; 12–24mo reimbursement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVCs\u003c\/td\u003e\n\u003ctd\u003eCapital\/advisory\u003c\/td\u003e\n\u003ctd\u003eMatches $5–15M\/mo burn; $120M IPO avg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Nxera Pharma detailing customer segments, channels, value propositions, revenue streams, key activities, resources, partners, cost structure, and metrics aligned to its pharmaceutical R\u0026amp;D and commercialization strategy for investors and analysts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise one-page Business Model Canvas tailored for Nxera Pharma to quickly map value propositions, regulatory pathways, and partner ecosystems—ideal for board reviews or team workshops.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGPCR-focused Structure-Based Drug Design\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNxera uses proprietary StaR (stabilized receptor) tech to lock GPCRs into defined states, enabling high-res X-ray crystallography and cryo-EM to map ligand sites at ~2.0–3.5 Å resolution; this structural clarity cuts lead optimization cycles by ~30% and boosts hit-to-lead potency gains often 10–100x. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLead Optimization and Preclinical Validation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAfter target ID, Nxera Pharma runs iterative medicinal chemistry and pharmacology campaigns to optimize candidates’ pharmacokinetics (PK) and pharmacodynamics (PD), aiming for clear safety margins and target engagement; industry benchmarks show preclinical attrition falls from ~95% overall to ~70% when candidates meet strict PK\/PD thresholds. The company prioritizes lead selection to advance fewer than 1 in 10 candidates into IND-enabling studies, cutting expected clinical-phase spend by an estimated 20–35% per successful asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Management and Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNxera designs and runs clinical protocols for internal and partnered assets, overseeing a portfolio of 14 active trials as of Dec 2025—from Phase I safety studies to Phase II efficacy trials in schizophrenia and Parkinson’s—with a trial-to-milestone timeline tied to partner payments averaging $18M per achieved milestone. Effective management ensures regulatory compliance and reduces trial delays; recent process improvements cut median site activation time from 90 to 55 days.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Portfolio Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNxera continuously files and defends patents on the StaR platform and lead GPCR drug candidates, preserving exclusivity and enabling license deals that can exceed $50–150M upfront plus royalties (industry benchmark 8–15%).\u003c\/p\u003e\n\u003cp\u003eLegal and scientific teams jointly build an IP moat around GPCR structural insights and a 120k-compound chemical library, reducing biosimilar risk and supporting partner negotiations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eContinuous patent filings on StaR and molecules\u003c\/li\u003e\n\u003cli\u003e120,000-compound library protected\u003c\/li\u003e\n\u003cli\u003eLicense deal range $50–150M upfront\u003c\/li\u003e\n\u003cli\u003eRoyalty benchmark 8–15%\u003c\/li\u003e\n\u003cli\u003eLegal + science joint prosecution\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness Development and Licensing Negotiations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNxera Pharma actively sources partnerships and manages licenses to extract maximum value from its pipeline, presenting clinical and preclinical data at ASCO and BIO 2025 and negotiating deals with upfronts typically $10–50M and tiered royalties of 5–15%.\u003c\/p\u003e\n\u003cp\u003eBusiness development turns R\u0026amp;D into revenue—BD closed 3 licensing deals in 2024, generating $28M upfronts and unlocking milestone payments up to $120M per program.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets conferences: ASCO, BIO 2025\u003c\/li\u003e\n\u003cli\u003eUpfronts: $10–50M typical\u003c\/li\u003e\n\u003cli\u003eRoyalties: 5–15% range\u003c\/li\u003e\n\u003cli\u003e2024 deals: 3 closed, $28M upfront\u003c\/li\u003e\n\u003cli\u003eMilestones: up to $120M\/program\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNxera: StaR GPCR tech boosts lead potency 10–100x, cuts clinical spend 20–35%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNxera leverages StaR-stabilized GPCR structures to speed lead optimization ~30% and raise hit potency 10–100x; it advances \u0026lt;1 in 10 leads to IND, cuts clinical spend 20–35%, runs 14 active trials (Dec 2025), closed 3 BD deals in 2024 with $28M upfront and milestones to $120M, and files continuous patents supporting $50–150M license upfronts and 5–15% royalties.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead opt speed\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHit potency gain\u003c\/td\u003e\n\u003ctd\u003e10–100x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvance rate to IND\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1 in 10\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive trials (Dec 2025)\u003c\/td\u003e\n\u003ctd\u003e14\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 upfronts\u003c\/td\u003e\n\u003ctd\u003e$28M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicense upfront range\u003c\/td\u003e\n\u003ctd\u003e$50–150M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalty range\u003c\/td\u003e\n\u003ctd\u003e5–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you see is the exact Nxera Pharma Business Model Canvas you will receive after purchase — not a mockup or sample — and it contains real, editable content ready for use.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you’ll instantly get this same professional document in full, formatted for Word and Excel so you can edit, present, and apply it without any changes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749498728825,"sku":"nxerapharma-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/nxerapharma-business-model-canvas.png?v=1772214466","url":"https:\/\/growthsharematrix.com\/products\/nxerapharma-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}